LONDON -- If you can keep your head while everyone around is losing theirs, you probably hold shares in GlaxoSmithKline (LSE:GSK) (NYSE:GSK). Last week's market mayhem won't have troubled this pharmaceutical giant's loyal army of long-term investors -- you don't measure an investment like Glaxo in days, but years and years.
GlaxoSmithKline is just the tonic in troubled times. As markets fret over Japan's last throw of the monetary dice and the Federal Reserve's plans to unwind QE, defensive investors will be pondering their options. Cash remains on the sick list. Gold bugs have been stung. Bond investors fear a bubble. Defensive FTSE 100 blue chips such as Glaxo shine by comparison.
You can get 2.5% on cash right now, but only if you lock your money away for five years with a bank you've never heard of. If you want easy access, you'll barely get 1.5%. Right now, Glaxo yields a far healthier 4.2%, with any share price growth on top. Better still, management hiked the dividend 6% to 18 pence in the first quarter: No savings account has such a progressive attitude to its customers. Share-price performance has been solid rather than spectacular. Glaxo is up 24% over one year, against 27% for the FTSE 100, but nobody buys this stock to gorge themselves on growth. You invest to line your portfolio's stomach and for those juicy dividends. Yet Glaxo has still risen a tasty 52% over the last three years, against 33% for the index
Glaxo aids recovery
Glaxo does have some problems. Sales and earnings have dipped slightly, and the global government spending squeeze won't help. It is under investigation by the OFT for allegedly abusing its dominant market position over antidepressant treatment Seroxat, a charge that Glaxo denies. But it has a healthy drugs pipeline and cash flow, and its plans to offload iconic brands Lucozade and Ribena could generate yet more cash to reinvest in the business or fund further share repurchases. Glaxo is already repurchasing between 1 billion pounds and 2 billion pounds of its shares. Earnings per share growth should be around 3% to 4% -- decent, but hardly daredevil. That's good enough for me right now.
Glaxo looks perfectly valued at 15.5 times earnings. That's a little too perfect for my liking. If the bond market boos Japan offstage or Bernanke fluffs his QE exit lines, Glaxo could become that little bit cheaper, while its yield would be even more generous. Now that would be a real tonic.
There are other great income opportunities out there, including Motley Fool's favorite income pick. Our analysts have singled out this FTSE 100 favorite because it offers a sky-high yield and great growth prospects. To find out what it is, download our free guide "Power Up Your Portfolio." Simply click here now.
Harvey Jones owns shares of GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Is a Dividend Cut Coming From GlaxoSmithKline plc?
Is the company's rich yield an opportunity for investors, or a warning of trouble ahead?
Better Buy: GlaxoSmithKline plc vs. Pfizer
Want dependable and rising dividends with potential for long-term capital growth? One of these companies stands out.
Here's What Cost GlaxoSmithKline PLC Nearly $10 Billion in Market Cap in October
Uh-oh! Could GlaxoSmithKline's industry-leading dividend be at risk?